A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).
JOURNAL OF CLINICAL ONCOLOGY. Bd. 34. H. 4. 2016
Erscheinungsjahr: 2016
Publikationstyp: Zeitschriftenaufsatz
| Geprüft: | Bibliothek |
Autoren
Zhu, Andrew X. (Autor)
Galle, Peter R. (Autor)
Kudo, Masatoshi (Autor)
Finn, Richard S. (Autor)
Yang, Ling (Autor)
Abada, Paolo (Autor)
Chang, Shao-Chun (Autor)
Llovet, Josep M. (Autor)
Klassifikation
DDC Sachgruppe:
Medizin
